Deficient eNOS Phosphorylation is a mechanism for diabetic vascular dysfunction contributing to increased stroke size

Qian Li, Dmitriy Atochin, Satoshi Kashiwagi, John Earle, Annie Wang, Emiri Mandeville, Kazuhide Hayakawa, Livius V. D'Uscio, Eng H. Lo, Zvonimir Katusic, William Sessa, Paul L. Huang

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Background and Purpose: Phosphorylation of eNOS, an important post-translational modulator of its enzymatic activity, is reduced in diabetes mellitus. We hypothesized that modulation of eNOS phosphorylation could overcome diabetic vascular dysfunction and improves the outcome to stroke. Methods: We used the db/db mouse model of type 2 diabetes mellitus. We mated db/db mice with eNOS knock-in mice that carry single amino acid mutations at the S1176 phosphorylation site; the phosphomimetic SD mutation (serine replaced by aspartate) shows increased eNOS enzymatic activity, whereas the unphosphorylatable SA mutation (serine replaced by alanine) shows decreased eNOS activity. We characterized the vascular anatomy, baseline physiological parameters, and vascular reactivity. We used the middle cerebral artery occlusion model of stroke and measured infarct volume and neurological deficits. Results: db/db mice showed diminished eNOS phosphorylation at S1176. eNOS SD and SA mutations do not change the vascular anatomy at the Circle of Willis, brain capillary density, heart rate, or arterial blood gases of db/db mice. The eNOS SD mutation, but not the SA mutation, lowers blood pressure and improves vascular reactivity to acetylcholine in db/db mice. The eNOS SD mutation reduces stroke size and neurological deficit after middle cerebral artery occlusion. Conclusions: Diminished eNOS phosphorylation is a mechanism of vascular dysfunction in db/db mice. We show here that modulation of the eNOS S1176 phosphorylation site in db/db mice is associated with improved vascular reactivity and improved outcome to stroke after middle cerebral artery occlusion.

Original languageEnglish
Pages (from-to)3183-3188
Number of pages6
JournalStroke
Volume44
Issue number11
DOIs
Publication statusPublished - Nov 2013
Externally publishedYes

Fingerprint

Blood Vessels
Stroke
Phosphorylation
Mutation
Middle Cerebral Artery Infarction
Serine
Anatomy
Circle of Willis
Aspartic Acid
Alanine
Type 2 Diabetes Mellitus
Acetylcholine
Diabetes Mellitus
Heart Rate
Gases
Blood Pressure
Amino Acids
Brain

Keywords

  • Diabetes mellitus
  • Endothelial cells
  • Nitric oxide

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Clinical Neurology
  • Advanced and Specialised Nursing

Cite this

Deficient eNOS Phosphorylation is a mechanism for diabetic vascular dysfunction contributing to increased stroke size. / Li, Qian; Atochin, Dmitriy; Kashiwagi, Satoshi; Earle, John; Wang, Annie; Mandeville, Emiri; Hayakawa, Kazuhide; D'Uscio, Livius V.; Lo, Eng H.; Katusic, Zvonimir; Sessa, William; Huang, Paul L.

In: Stroke, Vol. 44, No. 11, 11.2013, p. 3183-3188.

Research output: Contribution to journalArticle

Li, Q, Atochin, D, Kashiwagi, S, Earle, J, Wang, A, Mandeville, E, Hayakawa, K, D'Uscio, LV, Lo, EH, Katusic, Z, Sessa, W & Huang, PL 2013, 'Deficient eNOS Phosphorylation is a mechanism for diabetic vascular dysfunction contributing to increased stroke size', Stroke, vol. 44, no. 11, pp. 3183-3188. https://doi.org/10.1161/STROKEAHA.113.002073
Li, Qian ; Atochin, Dmitriy ; Kashiwagi, Satoshi ; Earle, John ; Wang, Annie ; Mandeville, Emiri ; Hayakawa, Kazuhide ; D'Uscio, Livius V. ; Lo, Eng H. ; Katusic, Zvonimir ; Sessa, William ; Huang, Paul L. / Deficient eNOS Phosphorylation is a mechanism for diabetic vascular dysfunction contributing to increased stroke size. In: Stroke. 2013 ; Vol. 44, No. 11. pp. 3183-3188.
@article{cf479360c5cc4d1f90364d65e4cfff02,
title = "Deficient eNOS Phosphorylation is a mechanism for diabetic vascular dysfunction contributing to increased stroke size",
abstract = "Background and Purpose: Phosphorylation of eNOS, an important post-translational modulator of its enzymatic activity, is reduced in diabetes mellitus. We hypothesized that modulation of eNOS phosphorylation could overcome diabetic vascular dysfunction and improves the outcome to stroke. Methods: We used the db/db mouse model of type 2 diabetes mellitus. We mated db/db mice with eNOS knock-in mice that carry single amino acid mutations at the S1176 phosphorylation site; the phosphomimetic SD mutation (serine replaced by aspartate) shows increased eNOS enzymatic activity, whereas the unphosphorylatable SA mutation (serine replaced by alanine) shows decreased eNOS activity. We characterized the vascular anatomy, baseline physiological parameters, and vascular reactivity. We used the middle cerebral artery occlusion model of stroke and measured infarct volume and neurological deficits. Results: db/db mice showed diminished eNOS phosphorylation at S1176. eNOS SD and SA mutations do not change the vascular anatomy at the Circle of Willis, brain capillary density, heart rate, or arterial blood gases of db/db mice. The eNOS SD mutation, but not the SA mutation, lowers blood pressure and improves vascular reactivity to acetylcholine in db/db mice. The eNOS SD mutation reduces stroke size and neurological deficit after middle cerebral artery occlusion. Conclusions: Diminished eNOS phosphorylation is a mechanism of vascular dysfunction in db/db mice. We show here that modulation of the eNOS S1176 phosphorylation site in db/db mice is associated with improved vascular reactivity and improved outcome to stroke after middle cerebral artery occlusion.",
keywords = "Diabetes mellitus, Endothelial cells, Nitric oxide",
author = "Qian Li and Dmitriy Atochin and Satoshi Kashiwagi and John Earle and Annie Wang and Emiri Mandeville and Kazuhide Hayakawa and D'Uscio, {Livius V.} and Lo, {Eng H.} and Zvonimir Katusic and William Sessa and Huang, {Paul L.}",
year = "2013",
month = "11",
doi = "10.1161/STROKEAHA.113.002073",
language = "English",
volume = "44",
pages = "3183--3188",
journal = "Stroke",
issn = "0039-2499",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

TY - JOUR

T1 - Deficient eNOS Phosphorylation is a mechanism for diabetic vascular dysfunction contributing to increased stroke size

AU - Li, Qian

AU - Atochin, Dmitriy

AU - Kashiwagi, Satoshi

AU - Earle, John

AU - Wang, Annie

AU - Mandeville, Emiri

AU - Hayakawa, Kazuhide

AU - D'Uscio, Livius V.

AU - Lo, Eng H.

AU - Katusic, Zvonimir

AU - Sessa, William

AU - Huang, Paul L.

PY - 2013/11

Y1 - 2013/11

N2 - Background and Purpose: Phosphorylation of eNOS, an important post-translational modulator of its enzymatic activity, is reduced in diabetes mellitus. We hypothesized that modulation of eNOS phosphorylation could overcome diabetic vascular dysfunction and improves the outcome to stroke. Methods: We used the db/db mouse model of type 2 diabetes mellitus. We mated db/db mice with eNOS knock-in mice that carry single amino acid mutations at the S1176 phosphorylation site; the phosphomimetic SD mutation (serine replaced by aspartate) shows increased eNOS enzymatic activity, whereas the unphosphorylatable SA mutation (serine replaced by alanine) shows decreased eNOS activity. We characterized the vascular anatomy, baseline physiological parameters, and vascular reactivity. We used the middle cerebral artery occlusion model of stroke and measured infarct volume and neurological deficits. Results: db/db mice showed diminished eNOS phosphorylation at S1176. eNOS SD and SA mutations do not change the vascular anatomy at the Circle of Willis, brain capillary density, heart rate, or arterial blood gases of db/db mice. The eNOS SD mutation, but not the SA mutation, lowers blood pressure and improves vascular reactivity to acetylcholine in db/db mice. The eNOS SD mutation reduces stroke size and neurological deficit after middle cerebral artery occlusion. Conclusions: Diminished eNOS phosphorylation is a mechanism of vascular dysfunction in db/db mice. We show here that modulation of the eNOS S1176 phosphorylation site in db/db mice is associated with improved vascular reactivity and improved outcome to stroke after middle cerebral artery occlusion.

AB - Background and Purpose: Phosphorylation of eNOS, an important post-translational modulator of its enzymatic activity, is reduced in diabetes mellitus. We hypothesized that modulation of eNOS phosphorylation could overcome diabetic vascular dysfunction and improves the outcome to stroke. Methods: We used the db/db mouse model of type 2 diabetes mellitus. We mated db/db mice with eNOS knock-in mice that carry single amino acid mutations at the S1176 phosphorylation site; the phosphomimetic SD mutation (serine replaced by aspartate) shows increased eNOS enzymatic activity, whereas the unphosphorylatable SA mutation (serine replaced by alanine) shows decreased eNOS activity. We characterized the vascular anatomy, baseline physiological parameters, and vascular reactivity. We used the middle cerebral artery occlusion model of stroke and measured infarct volume and neurological deficits. Results: db/db mice showed diminished eNOS phosphorylation at S1176. eNOS SD and SA mutations do not change the vascular anatomy at the Circle of Willis, brain capillary density, heart rate, or arterial blood gases of db/db mice. The eNOS SD mutation, but not the SA mutation, lowers blood pressure and improves vascular reactivity to acetylcholine in db/db mice. The eNOS SD mutation reduces stroke size and neurological deficit after middle cerebral artery occlusion. Conclusions: Diminished eNOS phosphorylation is a mechanism of vascular dysfunction in db/db mice. We show here that modulation of the eNOS S1176 phosphorylation site in db/db mice is associated with improved vascular reactivity and improved outcome to stroke after middle cerebral artery occlusion.

KW - Diabetes mellitus

KW - Endothelial cells

KW - Nitric oxide

UR - http://www.scopus.com/inward/record.url?scp=84888287927&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888287927&partnerID=8YFLogxK

U2 - 10.1161/STROKEAHA.113.002073

DO - 10.1161/STROKEAHA.113.002073

M3 - Article

VL - 44

SP - 3183

EP - 3188

JO - Stroke

JF - Stroke

SN - 0039-2499

IS - 11

ER -